Liver Cancer 2019 Sep 18
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.
Related Questions
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
New answer by Medical Oncologist at Keck School of Medicine of USC (November 18, 2020)
Unresectable HCC represents a broad group of HCC patients. For patients with liver limited disease without vascular invasion, I rely on tumor burden to determine whether to st...